InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, announced that it was awarded an Innovation Credit of EUR 1.3 million from the Dutch government. This award will support the development of miRNA-based therapeutics for the treatment of melanoma. The funding is granted by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation. The Innovation Credit is a credit aimed at funding development projects that have a high innovative character and strong commercial potential... 
More...
More...